Immunotherapy: Neoadjuvant and/or adjuvant? Literature review



Over the past two decades, immunotherapy has been developing rapidly and is making a real revolution in oncology. But unfortunately, not all expectations have been fulfilled to date, the relatively low effectiveness of immune checkpoint inhibitors (about 30%) forces clinicians to move forward in the search for new strategies. The march of immunotherapy, which began in metastatic patients, continued in the first line and adjuvant therapy, reached the starting point of treatment of operable patients – neoadjuvant systemic therapy. This review presents the latest research results on the use of various immuno-oncological drugs in the treatment of patients with non-metastic solid tumors. In addition, the role of nonspecific immunocorrection is sanctified, since there is no doubt that an oncological patient is an immunocompromised patient in need of accompanying therapy.